Organization | Biovail

Biovail Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Mississauga Canada (1982)

Status: Acquired by Bausch Health Companies (2010)

Organization Overview

First Clinical Trial

2003

NCT00847405

First Marketed Drug

1982

isosorbide (isordil)

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (5)

citalopram (celexa) (2005)

diltiazem (cardizem) (1989)

enalapril (vasotec) (1988)

isosorbide (isordil) (1961)

zolpidem (ambien) (2007)

Drugs in Phase 4 Trials (2)

Key: Biovail (0) Acquired (2)

idebenone (17 trials)

testosterone (delatestryl) (11 trials)

Drugs in Phase 3 Trials (2)

Key: Biovail (0) Acquired (2)

desmopressin (ddavp) (6 trials)

tetrabenazine (xenazine) (1 trial)

Drugs in Phase 2 Trials (5)

Key: Biovail (0) Acquired (5)

albuterol (proventil) (1 trial)

fipamezole (2 trials)

platelet-rich plasma (1 trial)

pol6014 (1 trial)

vamorolone (Agamree) (2 trials)

Drugs in Phase 1 Trials (15)

Key: Biovail (13) Acquired (2)

acetylsalicylic acid (aspirin) (2 trials)

amlodipine (norvasc) (2 trials)

carvedilol (coreg) (2 trials)

cefadroxil (duricef) (2 trials)

esomeprazole (nexium) (2 trials)

estradiol (progynon depot) (2 trials)

griseofulvin (grisactin) (2 trials)

meloxicam (mobic) (2 trials)

midazolam (versed) (1 trial)

norethindrone (2 trials)

omigapil (1 trial)

pravastatin (pravachol) (2 trials)

sitagliptin (januvia) (2 trials)

sumatriptan (zecuity) (1 trial)

trandolapril (mavik) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Peptic Ulcer (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 63
# of Trial APIs: 24